Noha A. Attia
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Noha A. Attia has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Ahmed A. Abdelaziz
Department of Microbiology and Immunology, Faculty of Pharmacy, Tanta University, Tanta, Egypt
2 shared publications - Amal M. Abo Kamer
Department of Microbiology and Immunology, Faculty of Pharmacy, Tanta University, Tanta, Egypt
2 shared publications - Fatma I. Sonbol
Department of Microbiology and Immunology, Faculty of Pharmacy, Tanta University, Tanta, Egypt
2 shared publications - Lamiaa Abdullah Al-Madboly
Department of Microbiology and Immunology, Faculty of Pharmacy, Tanta University, Tanta, Egypt
2 shared publications
Latest Publications
- Open Access
- 13 April 2026
- Published by Springer Nature in BMC Microbiology
- Vol. 26 (1)
Harnessing the power of ferulic acid as a dual-action strategy against biofilm-forming extensively drug-resistant Acinetobacter baumannii isolated from cancer patients: in vitro and in vivo study
The increasing prevalence of extensively drug-resistant Acinetobacter baumannii (XDRAb), particularly biofilm-producing strains, poses a significant threat to clinical management, especially in immunocompromised patients. This study investigates the potential of ferulic acid (FA) as a dual-function therapeutic agent with antibacterial and antibiofilm capabilities. A total of 34 XDRAb isolates were obtained from cancer patients, and FA’s activity was assessed using a range of in vitro assays and in vivo neutropenic rat wound infection model. FA exhibited marked antimicrobial activity against XDRAb (MIC: 512 to 1024 µg/mL). At su-binhibitory concentrations (¼ and ½ MIC), FA significantly inhibited biofilm formation by 43.2 and 67.6% and disrupted established biofilms by 29.4 and 54.8% ( p < 0.05), respectively. Consistent with these effects, FA also reduced cell surface hydrophobicity and exopolysaccharide production in XDRAb isolates. Microscopic imaging via light, scanning electron, and confocal laser scanning microscopy corroborated these findings, revealing substantial structural degradation of biofilms upon treatment. At the molecular level, FA significantly downregulated ( p < 0.05) the key biofilm-associated genes ( abaI , bfmR , bap , csuE , and pgaB ), as quantified by RT-qPCR. In vivo, FA significantly enhanced the wound healing rates (approximately 82%, p < 0.05) and reduced the wound bacterial burden ( p < 0.05). Histopathological examination showed near-complete restoration of epithelium architecture seven days post-treatment in the FA-treated group. Collectively, this study demonstrates that FA exerts combined antimicrobial and antibiofilm activities against XDRAb in preclinical models. Our findings indicate that FA interferes with multiple stages of biofilm development while exhibiting antibacterial activity at higher concentrations. These results support further investigation of FA as antibiofilm or adjunct candidate, particularly for localized biofilm-associated XDRAb infections.
- 13 April 2026
- Published by Springer Nature in BMC Microbiology
- Vol. 26 (1)
Open AccessHarnessing the power of ferulic acid as a dual-action strategy against biofilm-forming extensively drug-resistant Acinetobacter baumannii isolated from cancer patients: in vitro and in vivo study
The increasing prevalence of extensively drug-resistant Acinetobacter baumannii (XDRAb), particularly biofilm-producing strains, poses a significant threat to clinical management, especially in immunocompromised patients. This study investigates the potential of ferulic acid (FA) as a dual-function therapeutic agent with antibacterial and antibiofilm capabilities. A total of 34 XDRAb isolates were obtained from cancer patients, and FA’s activity was assessed using a range of in vitro assays and in vivo neutropenic rat wound infection model. FA exhibited marked antimicrobial activity against XDRAb (MIC: 512 to 1024 µg/mL). At su-binhibitory concentrations (¼ and ½ MIC), FA significantly inhibited biofilm formation by 43.2 and 67.6% and disrupted established biofilms by 29.4 and 54.8% ( p < 0.05), respectively. Consistent with these effects, FA also reduced cell surface hydrophobicity and exopolysaccharide production in XDRAb isolates. Microscopic imaging via light, scanning electron, and confocal laser scanning microscopy corroborated these findings, revealing substantial structural degradation of biofilms upon treatment. At the molecular level, FA significantly downregulated ( p < 0.05) the key biofilm-associated genes ( abaI , bfmR , bap , csuE , and pgaB ), as quantified by RT-qPCR. In vivo, FA significantly enhanced the wound healing rates (approximately 82%, p < 0.05) and reduced the wound bacterial burden ( p < 0.05). Histopathological examination showed near-complete restoration of epithelium architecture seven days post-treatment in the FA-treated group. Collectively, this study demonstrates that FA exerts combined antimicrobial and antibiofilm activities against XDRAb in preclinical models. Our findings indicate that FA interferes with multiple stages of biofilm development while exhibiting antibacterial activity at higher concentrations. These results support further investigation of FA as antibiofilm or adjunct candidate, particularly for localized biofilm-associated XDRAb infections.
- Open Access
- 11 April 2026
- Published by Springer Nature in Annals of Clinical Microbiology and Antimicrobials
- Vol. 25 (1)
Unlocking p-coumaric acid’s potential against biofilm-forming extensively drug-resistant Acinetobacter baumannii: in vitro and in vivo study
Background: The global rise of extensively drug-resistant Acinetobacter baumannii , particularly biofilm-forming strains, has drastically limited treatment options and created an urgent need for novel therapies to restore antibiotic efficacy. This study explored p-coumaric acid ( p -CA) as a potential dual-action agent to combat biofilm-associated XDR Acinetobacter baumannii infections and restore imipenem efficacy. Methods: Among 100 clinical Acinetobacter baumannii isolates, 32 were identified as XDR and exhibited resistance to imipenem. The antimicrobial and antibiofilm efficacy of p -CA was systematically evaluated through comprehensive in vitro assays and an in vivo rat infection model. Minimum inhibitory concentrations were determined via the broth microdilution method, and the potential modulation effect on imipenem efficacy was investigated. To assess biofilm inhibition and disruption, quantitative analyses were performed using the crystal violet staining technique, complemented by evaluating its impact on the bacterial cell surface hydrophobicity and exopolysaccharide production. Biofilm structural changes were analyzed via light, scanning electron, and confocal laser scanning microscopy. Additionally, the expression levels of key biofilm-associated genes were quantified via quantitative reverse transcription PCR. Results: The p -CA exhibited potent antimicrobial activity against the tested isolates (MIC: 512 µg/mL) and synergized with imipenem, reducing its MIC by 512-fold. At subinhibitory concentrations (¼–½ MIC), it inhibited biofilm formation (66.2–80.5%, p < 0.05) and disrupted pre-formed biofilms (45.8–71.3%, p < 0.05), likely via altered cell surface hydrophobicity and reduced EPS production. Microscopic imaging corroborated these findings, revealing substantial structural degradation of biofilms upon treatment. At the molecular level, p -CA significantly downregulated ( p < 0.05) the key biofilm-associated genes ( abaI , bfmR , bap , csuE , and pgaB ), as quantified by RT-qPCR. In vivo, the p -CA/imipenem combination significantly enhanced the survival rates (100%, p < 0.05) and reduced the lung bacterial burden ( p < 0.001). Histopathological examination showed near-complete restoration of alveolar architecture by 72 h post-treatment in the combination therapy group. Conclusion: These findings position p -CA as a promising dual-action adjuvant against XDR Acinetobacer baumannii infections, particularly in biofilm-associated contexts. It combines direct antimicrobial activity, biofilm disruption, and synergy with imipenem to address critical treatment gaps.
- 11 April 2026
- Published by Springer Nature in Annals of Clinical Microbiology and Antimicrobials
- Vol. 25 (1)
Open AccessUnlocking p-coumaric acid’s potential against biofilm-forming extensively drug-resistant Acinetobacter baumannii: in vitro and in vivo study
Background: The global rise of extensively drug-resistant Acinetobacter baumannii , particularly biofilm-forming strains, has drastically limited treatment options and created an urgent need for novel therapies to restore antibiotic efficacy. This study explored p-coumaric acid ( p -CA) as a potential dual-action agent to combat biofilm-associated XDR Acinetobacter baumannii infections and restore imipenem efficacy. Methods: Among 100 clinical Acinetobacter baumannii isolates, 32 were identified as XDR and exhibited resistance to imipenem. The antimicrobial and antibiofilm efficacy of p -CA was systematically evaluated through comprehensive in vitro assays and an in vivo rat infection model. Minimum inhibitory concentrations were determined via the broth microdilution method, and the potential modulation effect on imipenem efficacy was investigated. To assess biofilm inhibition and disruption, quantitative analyses were performed using the crystal violet staining technique, complemented by evaluating its impact on the bacterial cell surface hydrophobicity and exopolysaccharide production. Biofilm structural changes were analyzed via light, scanning electron, and confocal laser scanning microscopy. Additionally, the expression levels of key biofilm-associated genes were quantified via quantitative reverse transcription PCR. Results: The p -CA exhibited potent antimicrobial activity against the tested isolates (MIC: 512 µg/mL) and synergized with imipenem, reducing its MIC by 512-fold. At subinhibitory concentrations (¼–½ MIC), it inhibited biofilm formation (66.2–80.5%, p < 0.05) and disrupted pre-formed biofilms (45.8–71.3%, p < 0.05), likely via altered cell surface hydrophobicity and reduced EPS production. Microscopic imaging corroborated these findings, revealing substantial structural degradation of biofilms upon treatment. At the molecular level, p -CA significantly downregulated ( p < 0.05) the key biofilm-associated genes ( abaI , bfmR , bap , csuE , and pgaB ), as quantified by RT-qPCR. In vivo, the p -CA/imipenem combination significantly enhanced the survival rates (100%, p < 0.05) and reduced the lung bacterial burden ( p < 0.001). Histopathological examination showed near-complete restoration of alveolar architecture by 72 h post-treatment in the combination therapy group. Conclusion: These findings position p -CA as a promising dual-action adjuvant against XDR Acinetobacer baumannii infections, particularly in biofilm-associated contexts. It combines direct antimicrobial activity, biofilm disruption, and synergy with imipenem to address critical treatment gaps.